Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;19(11):e0314205.
doi: 10.1371/journal.pone.0314205. eCollection 2024.

Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers

Affiliations

Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers

Michael Bonert et al. PLoS One. .

Abstract

Brain metastases are frequent in neuropathology practices; however, the literature on their distribution is frequently derived from imaging studies. This work examined metastases of lung cancer to the brain through the lens of pathology specimens. All brain surgical pathology cases accessioned from 2011-2020 were retrieved from a regional laboratory. Specimens were classified by neuroanatomical location, diagnostic category, and diagnosis with a hierarchical free text string-matching algorithm. All reports classified as probable metastasis per algorithm were reviewed by a pathologist. Lung biomarkers and selected immunostains were retrieved with text parsing and reviewed. Among 4,625 cases of brain surgical resection specimens, 854 were classified as probable metastasis by the algorithm. On report review, 538/854 cases were confirmed as metastasis with a known primary site. The 538 cases were from 511 patients and 234/511 patients had lung primaries. Small cell lung cancer lesions were most frequently found in the cerebellum (17/30). Lesions from lung adenocarcinoma (59/164) and non-small cell carcinoma-not otherwise specified (NSCLC-NOS) (15/34) were most commonly found in the frontal lobe. Squamous cell carcinoma lesions were most commonly found in the frontal and occipital lobes (8/27). 72/234 cases were reported as NSCLC-NOS and could be further subclassified using immunostaining (41/72). Lung biomarker data were retrieved in ~38% of cases. PD-L1 positivity was dependent on neuroanatomical distribution (p = 0.04); other examined biomarkers were not. The distribution of lung tumours metastatic to the brain is dependent on the lung cancer subtype (p<0.001). The reporting of histologic subtype could be further optimized in the local environment.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.The corresponding author (MB) retains the copyright on the computer code that was written outside of his employment relationship with McMaster University/St. Joseph’s Healthcare Hamilton/Hamilton Regional Laboratory Medicine Program. The above does not in any way limit adherence to the PLOS ONE data availability policy, as found here: https://journals.plos.org/plosone/s/data-availability. There is no financial conflict of interest. There are no conflicts for the other authors.

Figures

Fig 1
Fig 1. The study methods in a flow chart.
HFTSMA = hierarchical free text string-matching algorithm; csv = formatted text output (tab or comma separated).
Fig 2
Fig 2. The brain metastases from the lung by neuroanatomical site.
This figure is applicable in the diagnostic context; if the neuroanatomical site is known, it answers the question “How likely is a metastasis from a lung tumour of subtype ‘X’?”.
Fig 3
Fig 3. The brain metastases by lung subtype.
This figure is applicable in the pathobiologic context; if the lung subtype is known, it answers the question “How likely is a metastasis to the neuroanatomical site ‘Y’?”.
Fig 4
Fig 4. Clustered heatmap showing the p-values calculated by Fisher’s exact test for all each pairing of neuroanatomical location and lung cancer subtype.
Neuroanatomical location abbreviations: FRO = frontal lobe, PAR = parietal lobe, TEM = temporal lobe, OCC = occipital lobe, CER = cerebellum. Lung cancer subtype abbreviations: AC = adenocarcinoma, SCC = squamous cell carcinoma, SCLC = small cell carcinoma, NSCLC = non-small cell carcinoma-NOS. The colours represent different p-value ranges: red is p = 0 to <0.05, pink is p = 0.05 to <0.1, white is p = 0.1 to <0.2, light blue is p = 0.2 to <0.4 and dark blue is p = 0.4 to 1.0.

Similar articles

References

    1. <References>. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al.. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012;123(2):205–22. https://pubmed.ncbi.nlm.nih.gov/22212630/. doi: 10.1007/s00401-011-0933-9 - DOI - PubMed
    1. Che W, Liu J, Fu T, Wang X, Lyu J. Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience. Curr Oncol. 2022;29(11):8374–89. https://pubmed.ncbi.nlm.nih.gov/36354720/. doi: 10.3390/curroncol29110660 - DOI - PMC - PubMed
    1. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705. https://pubmed.ncbi.nlm.nih.gov/12173339/. doi: 10.1002/cncr.10541 - DOI - PubMed
    1. Merkin RD, Chiang VL, Goldberg SB. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances in Medical Oncology. 2023;15:17588359231175438. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233588/. doi: 10.1177/17588359231175438 - DOI - PMC - PubMed
    1. Wang G, Xu J, Qi Y, Xiu J, Li R, Han M. Distribution Of Brain Metastasis From Lung Cancer. Cancer Manag Res. 2019;11:9331–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830371/. doi: 10.2147/CMAR.S222920 - DOI - PMC - PubMed

Substances